The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
about
Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney CancerMammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulationA yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor proteinIdentification of novel VHL target genes and relationship to hypoxic response pathwaysHIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activityThe forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanismThe von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repressionEAF2 suppresses hypoxia-induced factor 1α transcriptional activity by disrupting its interaction with coactivator CBP/p300von Hippel-Lindau disease: a clinical and scientific reviewState of the science: an update on renal cell carcinomaThe VHL tumor suppressor: master regulator of HIFHypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylationGenetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegansOncogenes strike a balance between cellular growth and homeostasisRINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionRenal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cystsAllosteric inhibition of hypoxia inducible factor-2 with small moleculesHypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.The roles of chromatin-remodelers and epigenetic modifiers in kidney cancerHypoxia-inducible factors in the kidneyReduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasionA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma modelsInactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulationBreaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkersHIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastomaCharacterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alphaU19/Eaf2 binds to and stabilizes von hippel-lindau protein.Front instabilities and invasiveness of simulated 3D avascular tumors.The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.HIF-1alpha: a valid therapeutic target for tumor therapyIntegrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma.MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
P2860
Q21090542-D724A89F-9DBA-4D51-9D11-D5F1D6E4F6D6Q24298432-1258973A-2710-491F-8700-339F734369E8Q24299850-D58E7B0B-C36C-47A7-805F-0304CFAB03C0Q24299968-37506D6B-C507-4F91-B97F-13A7FBB563DDQ24302129-9DCD638B-311B-4F8E-9D07-432D0AAF2870Q24302271-D3955250-C203-4464-84BA-474F8C178B17Q24304165-194D6F83-153E-4047-95C5-E5BEFF9D2BD9Q24306098-4A86DA9E-516C-4E50-BC90-CB6EE9940DE1Q24319939-6D3F15AE-7BEC-4511-B104-BDD05F2481A6Q24622030-FBF15FEE-DED6-4D7D-A5CA-E927C62323B9Q24630685-40C63493-2B38-4922-BF0C-7CA4B33BFA37Q24634592-09038280-9628-4B90-9AC0-FAEB2BE1A18DQ24651016-3890D08D-00A5-4ED0-B4A1-1BE7BE5EAD71Q24681460-AF370929-BD69-46AC-BC1F-4CBC11DF2631Q24684757-D6CFD99F-9027-4DF9-AC00-104D15AAB755Q24802803-8878E683-9CB8-4DB4-9298-9877F1A414C2Q24804603-06DC2FF7-7C2C-4687-9FD1-6F1DDDD66F07Q26798085-65709267-E798-4C7F-9FF6-75DFF0E59D01Q26853207-AD3E7467-733B-41A0-BA93-BE7D90597C81Q27025886-7FF096EC-27C2-4E42-92A8-C99427317760Q27309141-E62640FB-E65E-455A-BA1D-74B58EE94659Q27676596-2020C073-AFC8-4802-B44A-F81B3E9CB5D9Q27824855-A7E9C095-AB13-40F5-852D-B06A390DC176Q28083152-EBE676AB-F31B-4040-A242-111142140AE9Q28303287-1DC842D9-E634-4ABE-9A9D-A964AD530CF0Q28478577-7FF1190B-E772-4317-9E8C-AB6D684715FCQ28485220-2CE994E4-E691-4EC7-B953-6683411B6C6EQ28590550-69E7A17B-66CB-4CC6-A905-9F45ECC5236CQ29619687-A08CEB52-0D69-4947-9C3E-779851784CD6Q30472042-8445E19A-638F-46DE-837C-08D7BC02DE41Q33291872-95D739C0-3985-4BE9-A828-BF5C6706990CQ33540183-E7F53AB4-132B-4ABD-BBCD-37A3C1B5B870Q33590977-C70375B4-E9E1-4EAA-90A9-1F680ED624FFQ33593093-EF406ADB-5DE6-4889-B632-6467E10E1315Q33673803-F6ECE7CF-3FD1-42D3-8EDB-E729B772AEFEQ33705004-A93E021B-C1C2-4AB0-B920-FEB1F6BB317FQ33746822-D46A56D1-9414-41DF-9506-D8DE2ABCDBD8Q33799049-06596550-4195-4D97-8F7D-94C1B3FA948CQ33804675-9429464A-7984-458D-B40E-65ABD978A078Q33837015-D77EE1B8-97C3-4379-A456-1285D6B05708
P2860
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The contribution of VHL substr ...... loss in renal cell carcinoma.
@en
The contribution of VHL substr ...... loss in renal cell carcinoma.
@nl
type
label
The contribution of VHL substr ...... loss in renal cell carcinoma.
@en
The contribution of VHL substr ...... loss in renal cell carcinoma.
@nl
prefLabel
The contribution of VHL substr ...... loss in renal cell carcinoma.
@en
The contribution of VHL substr ...... loss in renal cell carcinoma.
@nl
P2093
P1433
P1476
The contribution of VHL substr ...... loss in renal cell carcinoma.
@en
P2093
James R Vasselli
Joseph Riss
Juan S Bonifacino
Richard D Klausner
W Marston Linehan
P304
P356
10.1016/S1535-6108(02)00044-2
P577
2002-04-01T00:00:00Z